Figure 2.

Developmental WHO motor milestones at baseline and following administration of OAV101 in treated children with (A) 2 copies of SMN2 and (B) 3 copies of SMN2. WHO developmental assessments were completed for 21 participants at baseline and follow up. Infants were followed for a median of 16 (2–26) months post dosing and median age at data cut off was 2 years (range 0.17 to 3.3 years). ¹³ [Colour figure can be viewed at wileyonlinelibrary.com]